News | Guidewires | April 10, 2019

Straight Tip Guidewires Will Continue to Lead Global Guidewire Market Demand

New report from Future Market Insights predicts growing number of nonsurgical options for neuroradiology procedures will drive market demand

Straight Tip Guidewires Will Continue to Lead Global Guidewire Market Demand

April 10, 2019 — According to a new research study, straight tip guidewires, with a current share of more than a third of the total market value, will retain the dominant position in neurovascular guidewires market through 2028. The report from Future Market Insights notes that aneurysms and intra-and extra-cranial angioplasty reflect highest applicability of neurovascular guidewires.

Furthermore hospitals, though anticipated to reflect limited investment opportunities in the neurovascular guidewire market, will remain the leading end-use segment with the maximum share in terms of revenue generation, according to the FMI report.

Increasing Number of Neurovascular Disease Treatment Alternatives

Neurovascular guidewires, among the latest innovations in the neurovascular disease treatment landscape, have been pushing the number of neurovascular surgeries since introduction. This according to the report will remain a key factor sustaining demand for neurovascular guidewires in the global market over the coming years.

As the advent of new technology has increased the number of treatment options for neurovascular diseases, treatment with neurovascular guidewires is gaining ground rapidly. This is owing to the relatively lower risk associated with surgical treatment over conventional surgeries. The usage of guidewires, along with new technologies such as coating-based guidewires, has contributed substantially to the treatment options for complex lesions that are treated surgically.

The increasing number of neurovascular neuroradiology procedures is also boosting the demand for access products. The number of neurovascular interventions is increasing with growing awareness among surgeons about the cost benefit associated with neurovascular guidewires. In addition, reimbursement policies for outpatient surgeries are also expected to propel neurovascular guidewires market revenue. Furthermore, an increase in the number of end users such as ambulatory surgical centers in underdeveloped and developing countries is boosting the number of outpatients cases, which is also expected to drive the overall market for neurovascular guidewires.

Favorable Reimbursement Scenario and Government Support

The growing prevalence and incidence of cerebral infarction, aneurysm and stroke is projected to fuel the demand for neurovascular guidewires. Growth in the number of patients suffering from ischemic stroke across the world is also estimated to boost the adoption of neurovascular guidewires during the forecast period. Similarly, increasing incidence of arteriovenous malformations is also contributing to growth in demand for neurovascular guidewires, as well as the increasing prevalence of intracranial and extracranial angioplasty.

Modifications in reimbursement policies are encouraging the number of outpatient procedures with neurovascular guidewires in developed countries. Government initiatives and local reimbursement policies pertaining to the usage of neurovascular guidewires are also expected to boost the market over the forecast period.

Rising awareness about cerebral infarction is also estimated to contribute to the growth of the market. Reimbursement policies for the treatment of brain aneurysm are also contributing as patients are not required to pay from their own pocket.

FMI’s report tracks some of the key companies operating in the neurovascular guidewire market, which include:

  • Boston Scientific Corp.;
  • Medtronic;
  • Penumbra;
  • Stryker;
  • Asahi Intecc;
  • Integer Holding Corp;
  • Cordis Corp;
  • CONMED Corp;
  • phenox GmbH; and
  • Integer Holding Corp., among others.

Watch the VIDEO: Basics of Interventional Guidewire Design and Function, an interview with Dimitri Karmpaliotis, M.D., Ph.D., FACC

For more information: www.futuremarketinsights.com

 

Related Guidewires Content

The Basics of Guide Wire Technology

Understanding the Design and Function of Guidewire Technology

Guidewires Comparison Chart

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init